Business
Three-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity™ Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as part of Featured Clinical Research during the 2025 Transcatheter Cardiovascular Therapeut
About this update from Medtronic Plc.
[{"type":"text","content":"Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications","length":281,"tagName":"p","attribs":{}},{"type":"text","content":"GALWAY, Ireland, Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity™ Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as part of Featured Clinical Research during the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference.","length":568,"tagName":"p"},{"type":"text","content":""Radiofrequency renal denervation with the Symplicity blood pressure procedure continues to demonstrate a durable and clinically meaningful blood pressure–lowering effect," said David Kandzari, M.D., chief, Piedmont Heart Institute and Cardiovascular Service and co-principal investigator of the SPYRAL clinical program. "Through three years, sustained reductions in blood pressure were observed among subjects treated with the Symplicity Spyral RDN system, including those from the treatment arm and the approximately three quarters of patients from the control arm that were later treated with Symplicity."","length":628,"tagName":"p"},{"type":"text","content":"At three years, patients who underwent RDN (N= 206) showed significantly greater reductions in both 24-hour ambulatory systolic blood pressure (ABPM) and office-based systolic blood pressure (OSBP) compared to sham patients (N= 131), despite similar medication burden:","length":268,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"24-hour ABPM: −14.0 mmHg in the RDN group vs. −9.3 mmHg in the sham group (treatment difference: −4.7 mmHg; p=0.0028)","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"OSBP: −18.5 mmHg in the RDN group vs. −11.7 mmHg in the sham group (treatment difference: −7.4 mmHg; p=0.0002)","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":...